BACKGROUND: Haptoglobin (H) is a glycoprotein that regulates the immune response. Serum haptoglobin levels are significantly higher in patients with advanced epithelial ovarian cancer (EOC) with poor survival. Different isoforms of haptoglobin have been found in the serum of patients with EOC. We studied the genetic susceptibility and outcome of patients with EOC correlated to H phenotypes. MATERIALS AND METHODS: Analyses of the H phenotypes were performed on sera from patients stored at -70°C. A modified method based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of sera was used, followed by western blotting. RESULTS: Seventy-nine consecutive patients with EOC and 63 healthy women were enrolled. Their mean (±S.D.) age was 58.9±12.46 years. Overall survival was 66 months (95% confidence interval=37.7-94.2). Similar distribution of haptoglobin phenotypes was observed in EOC and in healthy women. No significant correlation was found between haptoglobin phenotype, overall survival and time-to-progression. Fewer G3 tumors were found in patients with H2-2 compared with those with H1-2 (84.2% and 90.6%, respectively, p<0.04). No significant correlation was found between H phenotype and tumor markers or number of relapses. CONCLUSION: Although ours is a preliminary study based on a small population with scant significant findings, we hypothesize that patients with EOC with haptoglobin 2-2, might have a better prognosis because they present fewer G3 tumors and they may present a stronger immune response than patients with 1-1 and 1-2 phenotypes. Larger studies should be performed to assess the predictive value of haptoglobin phenotype in patients with EOC.

Haptoglobin phenotype and epithelial ovarian cancer / Mandato, Vd; Magnani, E; Abrate, M; Casali, B; Nicoli, D; Farnetti, E; Formisano, D; Pirillo, D; Ciarlini, G; DE Iaco, P; Strada, I; Zamagni, C; LA SALA, Giovanni Battista. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - ELETTRONICO. - 32:(2012), pp. 4353-4358.

Haptoglobin phenotype and epithelial ovarian cancer.

LA SALA, Giovanni Battista
2012

Abstract

BACKGROUND: Haptoglobin (H) is a glycoprotein that regulates the immune response. Serum haptoglobin levels are significantly higher in patients with advanced epithelial ovarian cancer (EOC) with poor survival. Different isoforms of haptoglobin have been found in the serum of patients with EOC. We studied the genetic susceptibility and outcome of patients with EOC correlated to H phenotypes. MATERIALS AND METHODS: Analyses of the H phenotypes were performed on sera from patients stored at -70°C. A modified method based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of sera was used, followed by western blotting. RESULTS: Seventy-nine consecutive patients with EOC and 63 healthy women were enrolled. Their mean (±S.D.) age was 58.9±12.46 years. Overall survival was 66 months (95% confidence interval=37.7-94.2). Similar distribution of haptoglobin phenotypes was observed in EOC and in healthy women. No significant correlation was found between haptoglobin phenotype, overall survival and time-to-progression. Fewer G3 tumors were found in patients with H2-2 compared with those with H1-2 (84.2% and 90.6%, respectively, p<0.04). No significant correlation was found between H phenotype and tumor markers or number of relapses. CONCLUSION: Although ours is a preliminary study based on a small population with scant significant findings, we hypothesize that patients with EOC with haptoglobin 2-2, might have a better prognosis because they present fewer G3 tumors and they may present a stronger immune response than patients with 1-1 and 1-2 phenotypes. Larger studies should be performed to assess the predictive value of haptoglobin phenotype in patients with EOC.
2012
32
4353
4358
Haptoglobin phenotype and epithelial ovarian cancer / Mandato, Vd; Magnani, E; Abrate, M; Casali, B; Nicoli, D; Farnetti, E; Formisano, D; Pirillo, D; Ciarlini, G; DE Iaco, P; Strada, I; Zamagni, C; LA SALA, Giovanni Battista. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - ELETTRONICO. - 32:(2012), pp. 4353-4358.
Mandato, Vd; Magnani, E; Abrate, M; Casali, B; Nicoli, D; Farnetti, E; Formisano, D; Pirillo, D; Ciarlini, G; DE Iaco, P; Strada, I; Zamagni, C; LA SALA, Giovanni Battista
File in questo prodotto:
File Dimensione Formato  
Mandato VD 2012 Anticancer Res.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 125.45 kB
Formato Adobe PDF
125.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/853337
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact